Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
Clozapine-induced Myocarditis in Korea: Analysis of a Nationwide Database and Comparison to Other Countries.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Jeonghoon, Jeong Hyunsu, Park Jung Su, Kang Nuree, Jeong Jae Hoon, Kim Se Hyun
Аннотация
OBJECTIVE: Clozapine, though the mainstay treatment for treatment-resistant schizophrenia, is associated with potentially fatal adverse reactions, including myocarditis. The incidence of clozapine-induced myocarditis (CIM) demonstrates geographic and ethnic variability; however, reports from Asia remain scarce. This study aimed to provide a comprehensive overview of CIM in Korea and compare findings with reports from other countries.
METHODS: CIM cases were identified from Korean National Health Insurance Service (NHIS) database based on diagnostic codes, prescription timelines, and clinical details. Patient characteristics and concomitant medications were analyzed. A PubMed search using a validated query was conducted to compare CIM in Korea with those reported in other regions.
RESULTS: From the NHIS database of 36,286 patients with schizophrenia spectrum disorders who were prescribed clozapine, 29 patients (0.08%) received myocarditis diagnosis. Among them, 9 patients (0.02%) who discontinued clozapine after the diagnosis could be considered probable CIM. Among these probable CIM cases, 4 male patients (0.01%) developed myocarditis within 30 days of clozapine initiation, while 5 patients developed myocarditis during the maintenance period. Two patients were found to have died from CIM. The literature review yielded 38 relevant articles on CIM incidence, including 4 from Asia, 4 from Europe, 3 from the Americas, 16 from Australia, and 4 from New Zealand. A comparison between countries demonstrated a lower incidence of CIM in Korea.
CONCLUSION: Consistent with the previous report, the incidence of CIM in Korea was less than 0.1%, which is lower than the incidences in other countries.
METHODS: CIM cases were identified from Korean National Health Insurance Service (NHIS) database based on diagnostic codes, prescription timelines, and clinical details. Patient characteristics and concomitant medications were analyzed. A PubMed search using a validated query was conducted to compare CIM in Korea with those reported in other regions.
RESULTS: From the NHIS database of 36,286 patients with schizophrenia spectrum disorders who were prescribed clozapine, 29 patients (0.08%) received myocarditis diagnosis. Among them, 9 patients (0.02%) who discontinued clozapine after the diagnosis could be considered probable CIM. Among these probable CIM cases, 4 male patients (0.01%) developed myocarditis within 30 days of clozapine initiation, while 5 patients developed myocarditis during the maintenance period. Two patients were found to have died from CIM. The literature review yielded 38 relevant articles on CIM incidence, including 4 from Asia, 4 from Europe, 3 from the Americas, 16 from Australia, and 4 from New Zealand. A comparison between countries demonstrated a lower incidence of CIM in Korea.
CONCLUSION: Consistent with the previous report, the incidence of CIM in Korea was less than 0.1%, which is lower than the incidences in other countries.